Allegra Faces Increasing Challenges In Rx Drug Arena
This article was originally published in The Tan Sheet
Executive Summary
Obstacles to marketing second generation, non-sedating antihistamine Allegra effectively as a prescription drug have escalated substantially in the past year, according to Aventis
You may also be interested in...
Aventis “Contingency Plans” For Allegra Include Outlicensing
Aventis is considering outlicensing the antihistamine Allegra (fexofenadine) as a "contingency plan" in the event that the product loses its sole-source prescription-only status
Schering: Competitor Switch Of Rx Antihistamine, Nasal Steroid Anticipated
Schering-Plough expects the over-the-counter switch or generic availability of a competing Rx antihistamine or nasal steroid to impact its 2004 fiscal year earnings
Pfizer’s Zyrtec Remains Strong As Rx Antihistamine Market Weakens
The many loratadine products now available in the OTC market have not been able to undercut sales for Pfizer's Zyrtec (cetirizine), according to the company